AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17102644
Drug: Meningococcal C
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal C conjugate (MCC) vaccines administered at the same time as DT/Td boosters
Trial: 17102644
Drug: Meningococcal C
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal C conjugate (MCC) vaccines administered a month before or after DT/Td boosters
Trial: 17102644
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of analgesics/antipyretic medication
Trial: 17102644
Drug: MCC vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCC vaccines under the above schedules
Trial: 11269570
Drug: Tolterodine L-tartrate
RxNorm normalized name: Tolterodine L-tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine L-tartrate 2 mg administered with a standardized medium-fat breakfast
Trial: 11269570
Drug: Tolterodine L-tartrate
RxNorm normalized name: Tolterodine L-tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine L-tartrate 2 mg administered on an empty stomach
Trial: 10998085
Drug: Nitroglycerine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine (1 mg h‐1)
Trial: 10998085
Drug: Nitroglycerine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine (2 mg h‐1)
Trial: 8792277
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml of milk containing B. longum B6 grown with lactose
Trial: 8792277
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml of milk containing B. longum B6 grown with lactose plus glucose
Trial: 8792277
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml of milk containing B. longum ATCC 15708 grown with lactose
Trial: 8792277
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml of lowfat milk (control)
Trial: 1379256
Drug: GHRH-(1-29) high
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH-(1-29) high dose (1 mg) sc injections twice daily for 14 days
Trial: 1379256
Drug: GHRH-(1-29) low
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH-(1-29) low dose (0.5 mg) sc injections twice daily for 14 days
Trial: 30711987
Drug: Comprehensive pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Comprehensive pharmaceutical interventions
Trial: 26782102
Drug: Intravenous glyceryltrinitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glyceryltrinitrate (GTN) at a maximum tolerable dosage (6.2 ± 1.5 mg/h)
Trial: 26782102
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of iloprost (10 μg/mL)
Trial: 26782102
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: intravenous or inhaled sodium chloride (NaCl) 0.9%
Trial: 19406521
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis indicated in all patients; overall adequacy of prophylaxis according to hospital protocol was 89.1%
Trial: 17664057
Drug: Anti-inflammatory blend
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory blend rich in polyunsaturated fatty acids (alpha-linolenic acid, 240 mg/d; eicosapentaenoic acid, 120 mg/d; stearidonic acid, 49 mg/d; gamma-linolenic acid, 73 mg/d)
Trial: 17664057
Drug: Inflammatory fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflammatory fat blend (arachidonic acid, 40 mg/d)
Trial: 15841721
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between Helicobacter DNA and IgG antibody responses
Trial: 12200947
Drug: Target-controlled propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target-controlled propofol and target-controlled remifentanil (3 ng mL‐1)
Trial: 12200947
Drug: Midazolam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.03 mg kg‐1), target-controlled remifentanil (3 ng mL‐1) and target-controlled propofol
Trial: 7635409
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFN‐alpha) treatment for 4 months
Trial: 2792176
Drug: Lactitol (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactitol (20-40 g per day for one month)
Trial: 28849265
Drug: Intraoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative chemotherapy (portal vein chemotherapy, intraluminal chemotherapy, and intraperitoneal chemotherapy) plus surgery
Trial: 26090383
Drug: RBTM (rabeprozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBTM (rabeprozole 20 mg bid., bismuth subcitrate 120 mg qid, tetracycline 500 mg qid, and metronidazole 250 mg qid)
Trial: 26090383
Drug: RATM (rabeprozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RATM (rabeprozole 20 mg bid., amoxicillin 1 g bid., tetracycline 500 mg qid, and metronidazole 250 mg qid)
Trial: 23497763
Drug: Mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron OCAS 50 mg after a high-fat breakfast
Trial: 23497763
Drug: Mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron OCAS 50 mg after a low-fat breakfast
Trial: 23497763
Drug: Mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron OCAS 100 mg after a high-fat breakfast
Trial: 23497763
Drug: Mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron OCAS 100 mg after a low-fat breakfast
Trial: 21258027
Drug: Pharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic therapy for smoking cessation
Trial: 21258027
Drug: Pharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic therapy for smoking cessation (short-term follow-up ≤ 12 weeks)
Trial: 21258027
Drug: Pharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic therapy for smoking cessation (mid-term follow-up 26 weeks)
Trial: 15590048
Drug: Piecewise splines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piecewise splines and rescue (treatment adjustment)
Trial: 8424497
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of glucose mixed with 100 U of human insulin (HI/100)
Trial: 8424497
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of glucose mixed with 100 U of bovine insulin (BI/100)
Trial: 8424497
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of glucose mixed with 50 U of human insulin (HI/50)
Trial: 8424497
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of glucose mixed with 50 U of bovine insulin (BI/50)
Trial: 25365778
Drug: Mindful awareness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful awareness and acceptance treatment (M)
Trial: 24024323
Drug: Erbanxiao solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erbanxiao solution
Trial: 24024323
Drug: Compound Kushen
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Kushen injection
Trial: 12554382
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in a rehabilitation centre in Tenerife for four weeks (Group 1, n=30)
Trial: 12554382
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in two similar centres in Norway for four weeks (Group 2, n=29)
Trial: 24155106
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1.2 g of elemental calcium in the form of calcium carbonate)
Trial: 24155106
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (in women taking at least 80% of the supplements)
Trial: 24155106
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium intake (diet and supplements)
Trial: 9175948
Drug: Ibuprofen 1
RxNorm normalized name: ibuprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 1 x 10 mg/kg, followed by 5 mg/kg 24 and 48 hours later
Trial: 9175948
Drug: Indomethacin 3
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 3 x 0.2 mg/kg at 12 hour intervals
Trial: 3547369
Drug: Ceforanide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceforanide (two 1 gm doses)
Trial: 3547369
Drug: Cephalothin (five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin (five doses)
Trial: 27144905
Drug: High-dose prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisone (60 mg/day)
Trial: 27144905
Drug: Low-dose prednisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisone (15 mg/day)
Trial: 27144905
Drug: Medium-dose prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-dose prednisone (30 mg/day)
Trial: 21294416
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg noni extract
Trial: 21294416
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg noni extract
Trial: 21294416
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg noni extract
Trial: 3730529
Drug: Promethazine 50
RxNorm normalized name: promethazine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 50 mg (innovator dosage form)
Trial: 3730529
Drug: Promethazine 50
RxNorm normalized name: promethazine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 50 mg (generic dosage form)
Trial: 3730529
Drug: Promethazine 50
RxNorm normalized name: promethazine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 50 mg (solution dosage form)
Trial: 23924290
Drug: Methylphenidate (MP)
RxNorm normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP) at 0.3 mg/kg twice daily for 2 weeks
Trial: 10867042
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (330 mL/d, 47.1 mg/d lycopene)
Trial: 8104724
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4.0 mg
Trial: 8104724
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.4 mg
Trial: 27009108
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 μg twice a day for 4 weeks, then 10 μg twice a day)
Trial: 23901094
Drug: Daily acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily acyclovir 400 mg twice daily
Trial: 20141265
Drug: Nonpsychodynamic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpsychodynamic therapies
Trial: 20823824
Drug: Cytoflavin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (20 ml/day intravenous for 10 days, then 2 tablets twice a day for 25 days)
Trial: 20823824
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy only (comparison group)
Trial: 15840055
Drug: Alfacalcidol 0.5
RxNorm normalized name: alfacalcidol 0.5 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 0.5 microg PO daily
Trial: 15840055
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin 200 IU every other day
Trial: 11964564
Drug: 4‐Methylpyrazole (10‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐Methylpyrazole (10‐15 mg/kg orally)
Trial: 9548634
Drug: Drug-free detention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug-free detention treatment program (DVA)
Trial: 2850322
Drug: LMW heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMW heparin (Fluxum) at doses of 4,000 or 8,000 I.U. Axa once a day by subcutaneous injection
Trial: 2850322
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin at doses of 5,000 I.U. two or three times a day by subcutaneous injection
Trial: 31721026
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 1 year
Trial: 31721026
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other hypoglycemic agents) for 1 year
Trial: 26362578
Drug: ω‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 polyunsaturated fatty acids (PUFAs) 1.2 g/day for 12 weeks
Trial: 26617271
Drug: Fennel 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fennel 5% vaginal cream (5 g/day for 8 weeks)
Trial: 24159791
Drug: Mexicor used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexicor used in combined therapy with statins for atherogenic dyslipidemia
Trial: 20564380
Drug: High-dose ursodeoxycholic
RxNorm normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ursodeoxycholic acid (UDCA) treatment (28-30 mg/kg/day)
Trial: 12509613
Drug: Clenoliximab (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenoliximab (0.05, 0.2, 1, 5, 10 or 15 mg/kg; 150 or 350 mg weekly x 4; or 350 or 700 mg every other week x 2)
Trial: 12509613
Drug: Clenoliximab (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenoliximab (higher doses, less frequently)
Trial: 11100963
Drug: Protein-repair therapy
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-repair therapy including naturally occurring compounds (isoflavonoids), aminoglycoside antibiotics, butyrate analogues, phosphodiesterase inhibitors, adenosine nucleotides, designer compounds (benzo[c]quinoliziniums), small peptide replacements
Trial: 6414955
Drug: Deroctyl (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deroctyl (sustained-release capsules)
Trial: 6414955
Drug: Euglucon (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglucon (regular tablets)
Trial: 26961114
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (target LDL-C <70 mg/dL)
Trial: 26961114
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy (target LDL-C ≥100 and <120 mg/dL)
Trial: 24760537
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 or 900 μg twice daily
Trial: 15649196
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg daily for 8 weeks
Trial: 8157043
Drug: Transnasal butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal butorphanol (2 mg) without oxymetazoline
Trial: 8157043
Drug: Transnasal butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal butorphanol (2 mg) with oxymetazoline
Trial: 8157043
Drug: Intravenous butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous butorphanol (2 mg)
Trial: 28968138
Drug: IIV4 (split-virion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4 (split-virion quadrivalent influenza vaccine)
Trial: 27595443
Drug: IIV3 (trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV3 (trivalent inactivated influenza vaccine)
Trial: 17940203
Drug: epoetin or
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epoetin or DAR treatment
Trial: 17940203
Drug: less than
RxNorm normalized name: IgA less than or equal to 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: less than 10% blasts, low and int‐1 International Prognostic Scoring System (IPSS), red blood cell transfusion independence, serum EPO level less than 200 IU/L
Trial: 10443731
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiotherapy with endocrine therapy
Trial: 2192098
Drug: Oxprenolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (160 mg initially, 320 mg subsequently)
Trial: 2192098
Drug: Chlorthalidone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (50 mg daily)
Trial: 2192098
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxprenolol (160 mg and 320 mg) and chlorthalidone (25 mg and 50 mg)
Trial: 2192098
Drug: Oxprenolol (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (monotherapy and combination therapy)
Trial: 22901437
Drug: SMS reminders
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminders for medication adherence
Trial: 24200515
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (COL) 20g daily for 12 weeks
Trial: 22778317
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (first-line chemotherapy followed by erlotinib)
Trial: 10233190
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) and two antibiotics (metronidazole, tetracycline) twice daily for 14 days
Trial: 7418351
Drug: Metoclopramide (Primperan)
RxNorm normalized name: metoclopramide Oral Solution [Primperan]
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (Primperan) administration prior to examination
Trial: 6149595
Drug: Fluperlapine (200-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluperlapine (200-600 mg/day)
Trial: 22301884
Drug: Mipomersen 200
RxNorm normalized name: mipomersen 200 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 200 mg/wk
Trial: 22301884
Drug: Mipomersen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 300 mg/wk
Trial: 22301884
Drug: Mipomersen 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 100 mg/wk
Trial: 22301884
Drug: Mipomersen (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen (100, 200, 300 mg/wk)
Trial: 2229524
Drug: Topical terbinafine
RxNorm normalized name: terbinafine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical terbinafine 1% cream
Trial: 338872
Drug: Intramuscular iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iron treatment
Trial: 31808278
Drug: Combined ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combined ranibizumab 0.5 mg/PRP
Trial: 23816960
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg per day
Trial: 17531723
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCA) with meperidine
Trial: 1488694
Drug: ORS and
RxNorm normalized name: ACE inhibitors and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS and Smectite (3.6 g/day) (32 cases)
Trial: 1488694
Drug: ORS and
RxNorm normalized name: ACE inhibitors and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS and Smectite (3.6 g/day)
Trial: 3003729
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 to 40 mg/day)
Trial: 31904175
Drug: Oral hydrolyzed
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrolyzed eggshell membrane (450 mg/d)
Trial: 29789130
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (300 ml/day for men, 230 ml/day for women)
Trial: 28316276
Drug: Levosimendan (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.2 μg/kg/min for 1 hour, followed by 0.1 μg/kg/min for 23 hours)
Trial: 21765345
Drug: Amifostine (10-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (10-100 mg/kg, intraperitoneal injection)